By extrapolation from the established profiles of approved GLP-1 receptor agonists including semaglutide (Wegovy SmPC, MHRA/EMC) and tirzepatide (Mounjaro SmPC, MHRA/EMC) clinicians should anticipate the need to review and potentially reduce antihypertensive doses as significant weight loss occurs, in line with BNF and NICE guidance principles
Still, it may progress into more severe forms of liver disease, such as nonalcoholic steatohepatitis (NASH) or cirrhosis, if not addressed, both of which can lead to permanent damage and reduced liver function
doi:10.1016/S2213-8587(17)30085-2 Rodbard HW, Lingvay I, Reed J, et al
A., Heerspink, H
Yet, there is no clinical research reporting on its effects on humans, so there is no guarantee it will work the same way or play any role in the growth of muscle and strength